HCAR2, the nicotinic acid receptor, has recently been reported to have BC tumor suppressing properties [4, 5]; thus, rare, non-synonymous variants in HCAR2 likely disrupt protein function, increasing BC susceptibility. This evidence concerns the gene HCAR2 and breast cancer.